HDM1005
Sponsors
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Conditions
Healthy ParticipantsObeseObstructive Sleep Apnea (OSA) and ObesityOverweightOverweight and/or Obesity
Phase 1
A Pharmacokinetic Study of HDM1005 Injection in Participants With Impaired Renal Function and Healthy Participants
Not yet recruitingNCT07559240
Start: 2026-05-15End: 2026-07-31Target: 30Updated: 2026-05-08
A Pharmacokinetic Study of HDM1005 Injection at Different Injection Sites
Active, not recruitingNCT07828197
Start: 2026-09-03End: 2026-11-01Target: 135Updated: 2026-09-18
Phase 3
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Not Receiving Positive Airway Pressure (PAP) Therapy
Not yet recruitingNCT07787260
Start: 2026-08-01End: 2028-06-01Target: 200Updated: 2026-08-26
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Receiving Positive Airway Pressure (PAP) Therapy
Not yet recruitingNCT07794397
Start: 2026-09-01End: 2028-11-01Target: 200Updated: 2026-08-31